Reasons Why Investors Should Consider Betting on Arvinas StockZacks Investment Research · Oct 13, 2026
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's DiseaseGlobeNewsWire · Oct 7, 2026
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®GlobeNewsWire · Oct 1, 2026
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 29, 2026
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology CandidateGlobeNewsWire · Sep 28, 2026
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.37 | $2.58 | Beat |
| May 12, 2026 | -$0.95 | -$0.90 | Beat |
| Feb 24, 2026 | -$0.55 | -$1.10 | Miss |
| Nov 5, 2025 | -$0.75 | -$0.48 | Beat |
| Aug 6, 2025 | -$0.87 | -$0.84 | Beat |
| May 1, 2025 | -$0.86 | $1.14 | Beat |